Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPSNASDAQ:MRSNNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$2.35-49.2%$4.08$2.25▼$8.54$433.19M2.251.07 million shs35.84 million shsMRSNMersana Therapeutics$0.34-6.9%$0.36$0.26▼$2.83$45.60M0.832.62 million shs1.71 million shsVRNAVerona Pharma PLC American Depositary Share$97.05+2.9%$75.47$14.14▼$97.17$8.03B0.211.32 million shs1.22 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways-49.24%-49.35%-46.10%-23.45%-62.34%MRSNMersana Therapeutics-6.91%-10.34%-3.32%-23.99%-84.01%VRNAVerona Pharma PLC American Depositary Share+2.89%+4.69%+29.30%+46.65%+547.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPSCOMPASS Pathways2.2481 of 5 stars3.43.00.00.01.90.80.6MRSNMersana Therapeutics3.8565 of 5 stars3.54.00.04.10.02.50.0VRNAVerona Pharma PLC American Depositary Share2.2865 of 5 stars2.53.00.00.03.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCOMPASS Pathways 2.86Moderate Buy$17.00623.40% UpsideMRSNMersana Therapeutics 3.00Buy$5.201,426.72% UpsideVRNAVerona Pharma PLC American Depositary Share 3.00Buy$101.104.17% UpsideCurrent Analyst Ratings BreakdownLatest VRNA, MRSN, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025CMPSCOMPASS PathwaysEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ In-Line$11.00 ➝ $6.006/23/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$76.00 ➝ $160.006/20/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$107.00 ➝ $138.006/18/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.00 ➝ $116.006/11/2025VRNAVerona Pharma PLC American Depositary ShareCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.006/11/2025VRNAVerona Pharma PLC American Depositary ShareJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$95.00 ➝ $110.006/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/2/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $90.005/27/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$12.005/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AMRSNMersana Therapeutics$40.50M1.05N/AN/A($0.08) per share-4.26VRNAVerona Pharma PLC American Depositary Share$42.28M195.41N/AN/A$2.56 per share37.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$155.12M-$1.99N/AN/AN/AN/A-81.75%-59.42%7/30/2025 (Estimated)MRSNMersana Therapeutics-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,235.00N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest VRNA, MRSN, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/A4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.1110.1810.18MRSNMersana Therapeutics13.351.831.83VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%MRSNMersana Therapeutics93.92%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%MRSNMersana Therapeutics13.00%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12093.56 million89.89 millionOptionableMRSNMersana Therapeutics150124.63 million108.43 millionOptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableVRNA, MRSN, and CMPS HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High After Analyst UpgradeJune 23 at 2:11 PM | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockJune 23 at 12:25 PM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by PFG Investments LLCJune 22 at 4:23 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Price Target Raised to $138.00 at Wells Fargo & CompanyJune 21 at 1:57 AM | americanbankingnews.comRoth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market ProspectsJune 20, 2025 | msn.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given New $138.00 Price Target at Wells Fargo & CompanyJune 20, 2025 | marketbeat.comRoth Capital Reiterates Buy Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)June 20, 2025 | americanbankingnews.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher Sells 80,000 Shares of StockJune 19, 2025 | insidertrades.comMission Wealth Management LP Purchases New Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)June 19, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in StockJune 18, 2025 | marketbeat.comVerona Pharma: An Impressive Initial LaunchJune 18, 2025 | seekingalpha.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth CapitalJune 18, 2025 | marketbeat.comTraders Purchase Large Volume of Verona Pharma Put Options (NASDAQ:VRNA)June 17, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?June 16, 2025 | marketbeat.comTraders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)June 16, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 400,000 SharesJune 16, 2025 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $4,560,000.00 in StockJune 16, 2025 | americanbankingnews.comJefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre LaunchJune 14, 2025 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in StockJune 14, 2025 | insidertrades.comCantor Fitzgerald Predicts Verona Pharma FY2025 EarningsJune 14, 2025 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in StockJune 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRNA, MRSN, and CMPS Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$2.35 -2.28 (-49.24%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.53 +0.18 (+7.66%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Mersana Therapeutics NASDAQ:MRSN$0.34 -0.03 (-6.91%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.35 +0.01 (+1.59%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$97.05 +2.73 (+2.89%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$97.75 +0.70 (+0.72%) As of 06/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
